



LUND UNIVERSITY

Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013

Ehinger, Anna; Malmström, Per; Bendahl, Pär Ola; Elston, Christopher W.; Falck, Anna Karin; Forsare, Carina; Grabau, Dorthe; Rydén, Lisa; Stål, Olle; Fernö, Mårten

Published in:
Acta Oncologica

DOI:
[10.1080/0284186X.2016.1237778](https://doi.org/10.1080/0284186X.2016.1237778)

2017

Document Version:
Peer reviewed version (aka post-print)

[Link to publication](#)

Citation for published version (APA):

Ehinger, A., Malmström, P., Bendahl, P. O., Elston, C. W., Falck, A. K., Forsare, C., Grabau, D., Rydén, L., Stål, O., & Fernö, M. (2017). Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. *Acta Oncologica*, 56(1), 68-74.
<https://doi.org/10.1080/0284186X.2016.1237778>

Total number of authors:
10

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

1 **Histological grade provides significant prognostic information in addition to**
2 **breast cancer subtypes defined according to St Gallen 2013**

3

4 Anna Ehinger^{1,2}, Per Malmström^{1,3}, Pär-Ola Bendahl¹, Christopher W. Elston⁴,
5 Anna-Karin Falck⁵, Carina Forsare¹, Dorthe Grabau†^{1,6}, Lisa Rydén^{7,8}, Olle Stål⁹ and
6 Mårten Fernö¹ for the South and South-East Swedish Breast Cancer Groups

7 ¹Department of Clinical Sciences, Division of Oncology and Pathology, Lund Cancer
8 Center at Medicon Village, Lund University, Lund, Sweden, ²Department of
9 Pathology and Cytology, Blekinge County Hospital, Karlskrona, Sweden,
10 ³Department of Oncology, Skåne University Hospital, Lund, Sweden, ⁴Department
11 of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United
12 Kingdom, ⁵Department of Surgery, Helsingborg Hospital, Helsingborg, Sweden,
13 ⁶Department of Pathology, Skåne University Hospital, Lund, Sweden, ⁷Department
14 of Clinical Sciences, Division of Surgery, Lund Cancer Center at Medicon Village,
15 Lund University, Lund, Sweden, ⁸Department of Surgery, Skåne University Hospital,
16 Lund, Sweden, ⁹Division of Oncology, Department of Clinical and Experimental
17 Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

18 † Deceased Dec 2015

19

20 Correspondence:

21 Mårten Fernö

22 Department of Clinical Sciences, Division of Oncology and Pathology,

23 Lund Cancer Center at Medicon Village, Building 404:B3

1 Scheelevägen 2
2 SE 223 81 Lund
3 Sweden

4

5 Running title: Histological grade is an important prognostic factor in breast cancer

6

7 **Abstract**

8 **Background:** The St Gallen surrogate definition of the intrinsic subtypes of breast
9 cancer consist of five subgroups based on estrogen receptor (ER), progesterone
10 receptor (PgR), human epidermal growth factor receptor type 2 (HER2), and Ki-67.
11 PgR and Ki-67 are used for discriminating between the 'Luminal A-like' and
12 'Luminal B-like (HER2-normal)' subtypes. Histological grade (G) has prognostic
13 value in breast cancer; however, its relationship to the St Gallen subtypes is not clear.
14 Based on a previous pilot study, we hypothesized that G could be a primary
15 discriminator for ER-positive/HER2-normal breast cancers that were G1 or G3,
16 while Ki-67 and PgR could provide additional prognostic information specifically for
17 patients with G2 tumors. To test this hypothesis, a larger patient cohort was
18 examined.

19 **Patients and methods:** Six hundred seventy-one patients (≥ 35 years of age, pT1-2,
20 pN0-1) with ER-positive/HER2-normal breast cancer and complete data for PgR, Ki-
21 67, G, lymph node status, tumor size, age, and distant disease-free survival (DDFS;
22 median follow-up 9.2 years) were included.

1 **Results:** ‘Luminal A-like’ tumors were mostly G1 or G2 (90%) while ‘Luminal B-
2 like’ tumors were mostly G2 or G3 (87%) and corresponded with good and poor
3 DDFS, respectively. In ‘Luminal B-like’ tumors that were G1 (n=23), no metastasis
4 occurred, whereas 14 out of 40 ‘Luminal A-like’ tumors that were G3 metastasized.
5 In subgroup analyses of G2 tumors, low PgR and high Ki-67 were both weakly
6 associated to an increased risk of distant metastases, hazard ratio (HR) and 95%
7 confidence interval (CI) 1.8 (0.95-3.4) and 1.5 (0.80-2.8), respectively.

8 **Conclusions:** Patients with ER-positive/HER2-normal/G1 breast cancer have a good
9 prognosis, similar to that of ‘Luminal A-like’, while those with ER-positive/HER2-
10 normal/G3 breast cancer have a worse prognosis, similar to that of ‘Luminal B-like’,
11 when assessed independently of PgR and Ki-67. Therapy decisions based on Ki-67
12 and PgR might thus be restricted to the subgroup G2.

13

14 **Introduction**

15 Adjuvant systemic therapy has improved survival among breast cancer patients, the
16 majority of which have estrogen receptor (ER)-positive, human epidermal growth
17 factor receptor type 2 (HER2)-normal disease. For patients with this subtype,
18 adjuvant endocrine therapy is usually recommended, often in combination with
19 chemotherapy. One of the greatest challenges within this group of patients is to
20 identify those with good prognosis for whom chemotherapy can be avoided [1]. In
21 2013, the St Gallen International Expert Consensus on the Primary Therapy of Early
22 Breast Cancer updated their surrogate panel, based on ER, Ki-67, progesterone
23 receptor (PgR), and HER2, for classification of the intrinsic subtypes of breast cancer

1 [2]. In this update, ER-positive/HER2-normal breast cancer was further divided into
2 'Luminal A-like' and 'Luminal B-like (HER2 normal)' subgroups wherein the
3 prognosis of patients with the former is better than that for the latter. In the 'Luminal
4 A-like' group, adjuvant chemotherapy might thus be avoided in the absence of other
5 negative prognostic factors.

6 Histological grade (G) has repeatedly been shown to be a strong and independent
7 prognostic factor [3-5], however, in 2013 the majority of St Gallen expert panelists
8 voted that G3 could not be used as a substitute for high Ki-67 [2]. In contrast, in a
9 pilot study that investigated the role of G in breast cancer prognosis in addition to
10 that afforded by the 2013 St Gallen classification system we found that in 161
11 premenopausal lymph node-negative patients with ER-positive/HER2-normal breast
12 cancer, G was strongly associated with St Gallen subtypes [7]. Indeed, 'Luminal A-
13 like' were mostly G1 or G2, whereas 'Luminal B-like' were usually G2 or G3 [6]. Of
14 the cases that diverged, a follow-up period of 10 years revealed that two out of four
15 patients with 'Luminal A-like' G3 breast cancer developed distant metastases and
16 hence had a prognosis more similar to that of 'Luminal B-like' breast cancer,
17 whereas of the three patients with 'Luminal B-like' breast cancer that were G1, not
18 one experienced relapse and thus their clinical outcome was more similar to that of
19 'Luminal A-like' breast cancer. These results, although based on a small number of
20 cases, suggest that, independent of PgR and Ki-67, patients with ER-positive/HER2-
21 normal breast cancers that are G1 might have a better prognosis than those with G3.
22 The primary aim of the present investigation was to use independent patient series to
23 confirm the additional prognostic value of G to that of the 2013 St Gallen surrogate

1 classification of ER-positive/HER2-normal breast cancer. We hypothesized that for
2 the ER-positive/HER2-normal subgroup of patients, G would be the first
3 discriminator for those with G1 or G3 tumors, while Ki-67 and PgR would provide
4 additional prognostic information specifically for patients with G2 tumors. As a
5 secondary aim, the prognostic importance of PgR and Ki-67 was evaluated in
6 patients with G2, ER-positive/HER2-normal breast cancer.

7

8 **Patients and Methods**

9 **Patients**

10 For the primary aim, we included breast cancer patients from two randomized
11 multicenter trials (Patient series I and II) and one additional cohort (Patient series III)
12 (Table 1). Patients with complete information regarding follow-up, number of
13 positive lymph nodes, tumor size, ER, PgR, HER2, Ki-67, and G were included
14 (Figure 1). Patients with at least one of the following characteristics were excluded:
15 ER negativity, HER2 positivity, <35 years of age, ≥ 4 positive lymph nodes, tumor
16 size >50 mm. Patients with these characteristics are most likely candidates for
17 adjuvant chemotherapy without consideration of other prognostic factors.

18 For the second aim, an additional 110 patients with G2 tumors were included (Patient
19 series IV; see below). These patients were not included when addressing the primary
20 aim as they were part of the pilot study [6].

21 **Patient series I:** (N=185). Premenopausal patients with stage II breast cancer
22 participated in a randomized trial comparing the effect of 2 years of tamoxifen

1 treatment versus no adjuvant systemic treatment. The original trial included 564
2 patients enrolled in the South and South-East Swedish Health Care Regions between
3 1986 and 1991 [7].

4 ***Patient series II:*** (N=103). Postmenopausal patients with stage II breast cancer were
5 enrolled, between 1983 and 1991, in a randomized trial launched by the Swedish
6 Breast Cancer group of 2 versus 5 years of adjuvant tamoxifen treatment (Swedish
7 Breast Cancer Cooperative Group 1996) [8]. From the original trial, paraffin
8 embedded tumor material was collected from a subgroup of patients treated with
9 tamoxifen for 2 years in the South Swedish Health Care Region, for comparison of
10 cytosol and immunohistochemistry methods for the analyses of ER and PgR [9]. This
11 subgroup was included in the present study.

12 ***Patient series III:*** Bone marrow metastases cohort (N=273). The purpose of the
13 original cohort was to study the prognostic importance of the presence of
14 cytokeratin-positive cells in the bone marrow. It included 555 patients recruited from
15 three hospitals in the South Swedish Health Care Region between 1999 and 2003
16 [10].

17 ***Patient series IV:*** SB91b (N=110). Premenopausal, lymph node-negative women
18 were enrolled between 1991 and 1994 in a trial administrated by the South Swedish
19 Breast Cancer Group, for evaluation of the prognostic importance of prospectively
20 analyzed S-phase fraction by flow cytometry [11]. The original trial included 237
21 patients of which 110 patients with G2 tumors were included in the present study.

22

1 **Evaluation of histological grade**

2 Histological grade of whole tissue sections was re-evaluated by breast pathologists
3 according to Elston and Ellis [3], as previously described for patient series I–III.
4 Patient series IV was re-evaluated by one of the authors of the present study (CWE)
5 using the same guidelines.

6

7 **Analysis of ER, PgR, Ki-67, and HER2**

8 The expression levels of ER, PgR, Ki-67, and HER2 were evaluated on whole
9 sections or tissue microarrays as previously described [7, 12, 13]. Two core biopsies
10 were evaluated from each formalin-fixed, paraffin-embedded breast cancer tissue,
11 and the one with the highest percentage of positively stained cells was chosen. All
12 cores were 0.6 mm in diameter with the exception of those used for ER and PgR
13 analyses in Patient material IV that were 1.0 mm in diameter.

14 *Cut-offs:* ER and PgR positivity were defined as >10% stained nuclei, high Ki-67 as
15 >20% stained nuclei, and HER2 positivity as 3+ or amplified 2+. It should be
16 mentioned that since ER and PgR had previously been analyzed and reported in
17 categories (positive vs. negative), we could not strictly apply the cut-offs according
18 to the St Gallen recommendations (ER positivity: $\geq 1\%$ and high PgR: $\geq 20\%$). Based
19 on our experience from one of the included cohorts (SB91B), however, only a very
20 small percentage of the tumors would have been influenced by this difference.

21

22 **The 2013 St Gallen classification of intrinsic subtypes**

1 St Gallen classification, based on ER, PgR, Ki-67, and HER2, was used to divide
2 ER-positive/HER2-normal breast cancer cases into two intrinsic subtypes, as
3 follows:

4 'Luminal A-like': ER-positive, PgR-positive, HER2-normal, and low Ki-67;

5 'Luminal B-like (HER2-normal)': ER-positive, HER2-normal, and one or both of
6 high Ki-67 and PgR-negative.

7

8 **Statistics**

9 Distant disease-free survival (DDFS) was chosen as the endpoint in the present
10 study. Differences in DDFS between subgroups of patients were evaluated using
11 Kaplan-Meier estimates and log-rank tests. All tests were stratified for patient series.
12 Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were estimated
13 using Cox regression, also stratified for patient series. Owing to violations of
14 proportional hazards assumptions for most variables included in the models, the
15 follow-up was restricted to the first 10 years after diagnosis. This action led to fewer
16 problems with non-proportional effects, but all effects should nevertheless be
17 interpreted as average effects over time and not as constant effect estimates valid
18 independent of follow-up time. All analyses were carried out using Stata version 14
19 (StataCorp LP, College Station, TX, USA, 2015).

20

21 **Results**

22 **Histological grade in 'Luminal A-like' and 'Luminal B-like (HER2-normal)'**
23 **breast cancer**

1 The 2013 St Gallen International Panel of Experts guidelines were used to classify
2 breast cancers from patient series I–III. According to these guidelines, 390 (70%) of
3 the 561 ER-positive/HER2-normal tumors were classified as ‘Luminal A-like’ while
4 the remaining 171 (30%) as ‘Luminal B-like’ (Table 2). In terms of prognosis, after a
5 median follow-up of 9.3 years for patients alive and free from distant metastases, the
6 latter subgroup had significantly worse DDFS compared with the former (HR=1.5,
7 95% CI: 1.0–2.3; Figure 2a). The distribution of G in these two subgroups was also
8 reviewed. The majority of ‘Luminal A-like’ tumors were either G1 or G2 (350/390;
9 90%), whereas a high proportion of Luminal B-like tumors were G2 or G3 (148/171;
10 87%; Table 2). Notably, among the 40 patients with Luminal A-like tumors that were
11 G3, 14 (35%) developed distant metastases during the follow-up period. In contrast,
12 of the twenty-three patients with ‘Luminal B-like’ breast cancers that were G1, none
13 developed distant metastases during follow-up (median follow-up for these 23
14 patients: 9.4 years, range: 5.5–10 years). The prognostic importance of G3 in
15 ‘Luminal A-like’ and G1 in ‘Luminal B-like’ breast cancer is further illustrated in
16 Figure 3a. Because most patients with ER-positive/HER2-normal breast cancer are
17 treated with adjuvant endocrine therapy, the prognostic value of St Gallen
18 classification was examined in endocrine-treated patients separately (Figure 2b).
19 Similar to the results above, DDFS was worse for patients with ‘Luminal B-like’
20 compared with that for those with ‘Luminal A-like’ breast cancers (HR=1.6, 95% CI:
21 0.98–2.7). Similarly, when G was also accounted for, the prognostic importance of
22 G3 in ‘Luminal A-like’ and G1 in ‘Luminal B-like (HER2-normal)’ breast cancer as
23 indicators of poor and good prognosis, respectively, was also confirmed in this
24 subgroup of patients (Figure 3b).

1

2 To further assess prognostic factors in our study cohort, multivariable analysis was
3 performed including G, St Gallen subtypes, tumor size, lymph node status, and
4 patient age. Among these, only G and lymph node status were found to be significant
5 prognostic factors (Table 3a). Similar results were obtained when patients treated
6 with adjuvant endocrine therapy were analyzed separately (Table 3b).

7

8 **PgR and Ki-67 in G2 breast cancer**

9 Because G2 was not clearly associated with prognosis of either Luminal A-like or
10 Luminal B-like breast cancer, PgR and Ki-67 were evaluated as possible prognostic
11 discriminators in G2 tumors. Although both PgR negativity and high Ki-67 were
12 associated with poor prognosis in G2 tumors, univariable analyses showed weak
13 evidence for prognostic discrimination (PgR (negative vs. positive): HR=1.8, 95%
14 CI: 0.95–3.4; Ki-67 (high vs. low): HR=1.5, 95% CI: 0.80–2.8; Figure 4a–b).

15

16 **Discussion**

17

18 In the present study, histological grade (G) added prognostic information to that
19 obtained using the 2013 St Gallen surrogate definition for the intrinsic subtypes of
20 breast cancer. Our findings confirm that breast cancers designated ER-
21 positive/HER2-normal that are G1 represent a good prognosis group, with a
22 prognosis similar to that of ‘Luminal A-like’ breast cancer. In contrast, ER-
23 positive/HER2-normal breast cancers that are G3 have worse prognosis, similar to
24 that of ‘Luminal B-like’ breast cancer. Notably, this could be ascertained

1 independent of Ki-67 and PgR. Moreover, these findings were essentially unchanged
2 when the effects of G and St Gallen classification on prognosis were assessed in
3 patients treated with adjuvant endocrine therapy alone. This therapy is generally
4 recommended for patients with ER-positive/HER2-normal breast cancer, alone or as
5 chemo-endocrine therapy. Based on our findings, the importance of Ki-67 and PgR
6 could be restricted to G2 breast cancers for the discrimination between good and
7 poor prognosis in ER-positive/HER2-normal breast cancer. Using gene expression
8 profiling, it has previously been shown that patients with histological grade 2 tumors
9 in a similar way could be subdivided into one group with good prognosis and one
10 group with poor prognosis [14]. It is interesting to note that most of these genes were
11 associated to cell cycle regulation and proliferation. The patients in our study were
12 selected from two randomized trials and two prospectively collected cohorts, and
13 were diagnosed between 1983 and 2003. In three of these series, the selection of
14 patients was based on menopausal status and stage of disease. It should therefore be
15 of value to confirm the present results in a truly populations-based series of breast
16 cancer patients.

17

18 In our study, 10% of 'Luminal A-like' were G3 and 13% of 'Luminal B-like' were
19 G1. A recent publication by Maisonneuve and co-workers obtained comparative
20 figures of 2.5% and 4.6%, respectively [15] as did Engstrøm and colleagues, who
21 reported 10.3% G3 in 'Luminal A-like' and 8.0% G1 in 'Luminal B-like' in a study
22 of 682 patients with ER-positive/HER2-normal breast cancer [16]. The occurrence of
23 poorly differentiated luminal A tumors (14.1%) as well as well-differentiated luminal
24 B tumors (9.4%) has also been demonstrated in a study based on the PAM50 gene set

1 [17]. Although accounting for a small percentage of cases, because G3 in 'Luminal
2 A-like' and G1 in 'Luminal B-like' inverted the expected prognosis dictated by the
3 St Gallen subtypes alone, these findings could critically influence disease treatment
4 for patients of these subgroups.

5

6 Similar to our study, Maisonneuve and colleagues suggested that G could be
7 incorporated as a first discriminator for ER-positive/HER2-normal breast cancer,
8 where G1 was a strong indicator for the 'Luminal A-like' subtype and G3 for the
9 'Luminal B-like'. The main focus of their study was, however, to evaluate the
10 prognostic importance of PgR and its relation to Ki-67 in the ER-positive/HER2-
11 normal breast cancer subgroup. Both Ki-67 and PgR have been reported to be of
12 prognostic importance for ER-positive disease in several studies [18, 19]. Indeed,
13 based on the study of Prat and colleagues [20], PgR was introduced into the St
14 Gallen breast cancer subtype definition in 2013. Maisonneuve and co-workers
15 showed that the prognostic importance of PgR was restricted to the intermediate Ki-
16 67 subgroup (14–20%), and that it did not provide any additional prognostic
17 information for the subgroups with either low (<14%) or high (\geq 20%) Ki-67 [16].
18 Subgroup analyses in our study, which was focused on G as the initial watershed,
19 showed inconclusive results regarding the prognostic effect of Ki-67 and PgR
20 ($P=0.21$ and $P=0.068$, respectively). The weak evidence may, however, be a power
21 problem, since in these subgroup analyses the number of patients and events are
22 small; 14 events in the PgR negative group ($n=67$) and 12 events in the high Ki-67
23 subgroup ($n=56$). In this context it should also be mentioned that the prognostic
24 importance of considering G3 for 'Luminal A-like' tumors was based on 40 patients

1 with 14 events. At the 2015 St. Gallen Consensus Conference, the majority of the
2 Panel accepted a threshold value of Ki-67 within the range 20%–29% (21). The
3 estimated prognostic effect of Ki-67 would most likely have been slightly different
4 for other cut-offs in this interval, but we have not explored that in the present dataset.
5 Instead we stick to the pre-defined cut-off 20%.

6
7
8 One drawback with G, however, is its limited inter-observer reproducibility [22, 23].
9 In spite of this, it has repeatedly been shown to be a strong prognostic factor [3-5].
10 Furthermore, it is cheap and easily evaluated routinely in the clinical setting. Also,
11 by using strict guidelines, the concordance between different evaluators can be
12 improved [24]. In this context, it should be mentioned that limited inter-observer
13 reproducibility is also a well-known problem for Ki-67 [25].

14
15 In conclusion, our findings suggest that patients above or equal to the age of 35 years
16 at diagnosis with T1-2, N0-1, ER-positive/HER2-normal/G1 breast cancer have a
17 prognosis similar to that of ‘Luminal A-like’, without consideration of Ki-67 and
18 PgR. For this group of patients, chemotherapy might be avoided in the absence of
19 other adverse prognostic factors. In contrast, patients with ER-positive/HER2-
20 normal/G3 breast cancer have a worse prognosis, similar to that of ‘Luminal B-like’.
21 Therapy decisions based on Ki-67 and PgR might thus be restricted to the ER-
22 positive/HER2-normal/G2 subgroup of breast cancers.

23

1 **ACKNOWLEDGEMENTS**

2

3 We are indebted to participating departments of the South Swedish Breast Cancer
4 Group and South East Swedish Breast Cancer Group for providing samples and
5 clinical follow-up. The study was supported by funds from the Swedish Cancer
6 Society, the Gunnar Nilsson Cancer Foundation, the Mrs. Berta Kamprad
7 Foundation, the Anna and Edwin Bergers Foundation, the Swedish Breast Cancer
8 Association (BRO), the Swedish Cancer and Allergy Foundation, The Scientific
9 Committee of Blekinge County Council, Skåne County Council's Research and
10 Development Foundation, and Governmental Funding of Clinical Research within
11 the National Health Service.

12

1 **Figure Legends**

2

3 **Figure 1**

4 Cohort flow diagram.

5

6 **Figure 2**

7 Distant disease-free survival (DDFS) by St Gallen subtypes, 'Luminal A-like' and
8 'Luminal B-like (HER2 normal)', for all patients (a) and for patients treated with
9 adjuvant endocrine therapy alone (b).

10

11 **Figure 3**

12 Distant disease-free survival (DDFS) by histological grade (G) and St Gallen
13 subtypes, 'Luminal A-like' and 'Luminal B-like (HER2 normal)', for all patients (a)
14 and for patients treated with adjuvant endocrine therapy alone (b).

15

16 **Figure 4**

17 Distant disease-free survival (DDFS) in ER-positive/HER2-normal, G2 breast cancer
18 stratified by PgR (negative vs. positive; a). DDFS in G2 tumors stratified by Ki-67
19 (high vs. low; b).

1 **References**

2

3 1. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International
4 Web-based consultation on priorities for translational breast cancer research. *Breast*
5 *Cancer Res* 2007; 9(6);R81.

6 2. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann
7 B, et al. Personalizing the treatment of women with early breast cancer: highlights of
8 the St Gallen International Expert Consensus on the Primary Therapy of Early Breast
9 Cancer 2013. *Ann Oncol* 2013;24(9):2206-23.

10 3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value
11 of histological grade in breast cancer: experience from a large study with long-term
12 follow-up. *Histopathology* 1991;19(5):403-10.

13 4. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT.
14 The Nottingham Prognostic Index applied to 9,149 patients from the studies of the
15 Danish Breast Cancer Cooperative Group (DBCG). *Breast Cancer Res Treat*
16 1994;32(3):281-90.


17

18 5. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains
19 a prognostic factor for breast cancer regardless of the number of positive lymph
20 nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER
21 Program. *Arch Pathol Lab Med* 2014;138(8):1048-52.

- 1 6. Ehinger A, Bendahl PO, Elston CW, Malmström P, Grabau D, Fernö M for the
2 South Swedish Breast Cancer Group. The role of histological grade in discrimination
3 between Luminal A-like and Luminal B-like subtypes in a series of premenopausal
4 breast cancer patients. In: Springer, editor. 26th European Congress of Pathology;
5 August 2014; London, UK: Virchows Arch; 2014. p. 123.
- 6 7. Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, et al. Two
7 years of adjuvant tamoxifen in premenopausal patients with breast cancer: a
8 randomised, controlled trial with long-term follow-up. *Eur J Cancer* 2005;41(2):256-
9 64.
- 10 8. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five
11 years of adjuvant tamoxifen for postmenopausal early stage breast cancer. *J Natl*
12 *Cancer Inst* 1996;88(21):1543-9.
- 13 9. Chebil G, Bendahl PO, Idvall I, Ferno M. Comparison of immunohistochemical
14 and biochemical assay of steroid receptors in primary breast cancer--clinical
15 associations and reasons for discrepancies. *Acta Oncol* 2003;42(7):719-25.
- 16 10. Falck AK, Bendahl PO, Ingvar C, Isola J, Jonsson PE, Lindblom P, et al.
17 Analysis of and prognostic information from disseminated tumour cells in bone
18 marrow in primary breast cancer: a prospective observational study. *BMC Cancer*
19 2012;12:403.
- 20 11. Malmstrom P, Bendahl PO, Boiesen P, Brunner N, Idvall I, Ferno M. S-phase
21 fraction and urokinase plasminogen activator are better markers for distant
22 recurrences than Nottingham Prognostic Index and histologic grade in a prospective
23 study of premenopausal lymph node-negative breast cancer. *J Clin Oncol*
24 2001;19(7):2010-9.

- 1 12. Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M. The
2 prognostic value of Ki67 is dependent on estrogen receptor status and histological
3 grade in premenopausal patients with node-negative breast cancer. *Mod Pathol*
4 2010;23(2):251-9.
- 5 13. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, et al.
6 Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-
7 negative breast carcinoma. *Clin Cancer Res* 2007;13(7):1987-94.
- 8 14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression
9 profiling in breast cancer: Understanding the molecular basis of histologic grade to
10 improve prognosis. *J Natl Cancer Inst* 2006; 98 (4):262-72.
- 11 15. Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M,
12 Dellapasqua S, et al. A revised clinico-pathological surrogate definition of Luminal
13 A intrinsic breast cancer subtype. *Breast Cancer Res* 2014;16(3):R65.
- 14 16. Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et
15 al. Molecular subtypes, histopathological grade and survival in a historic cohort of
16 breast cancer patients. *Breast Cancer Res Treat* 2013;140(3):463-73.
- 17 17. Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, et al.
18 PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical
19 molecular markers. *BMC Med Genomics* 2012;5:44.
- 20 18. Braun L, Mietzsch F, Seibold P, Schneeweiss A, Schirmacher P, Chang-Claude J,
21 et al. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-
22 prognostic relevance of progesterone receptor loss. *Mod Pathol* 2013;26(9):1161-71.


- 1 19. Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, et al.
2 Progesterone receptor expression is an independent prognostic variable in early
3 breast cancer: a population-based study. *Br J Cancer* 2013;110(3):565-72.
- 4 20. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al.
5 Prognostic significance of progesterone receptor-positive tumor cells within
6 immunohistochemically defined luminal A breast cancer. *J Clin Oncol*
7 2013;31(2):203-9.
- 8 21. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et
9 al. Tailoring therapies--improving the management of early breast cancer: St Gallen
10 International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
11 *Ann Oncol.* 2015 Aug;26(8):1533-46.
- 12 22. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E, Idvall I, et al.
13 Histologic grading in breast cancer--reproducibility between seven pathologic
14 departments. South Sweden Breast Cancer Group. *Acta Oncol* 2000;39(1):41-5.
- 15 23. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma. A
16 reproducibility study. *Cancer* 1994;73(11):2765-70.
- 17 24. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, et al. Impact of a
18 national external quality assessment scheme for breast pathology in the UK. *J Clin*
19 *Pathol* 2006;59(2):138-45.
- 20 25. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al.
21 An international ki67 reproducibility study. *J Natl Cancer Inst* 2013;105(24):1897-
22 906.



^aExcluded= inclusion criteria's not fulfilled
^bMissing info = missing information on inclusion variables


DDFS by St Gallen subtype

a



# at risk	0	2	4	6	8	10
Lum A 390	373	338	304	254	137	
Lum B 171	162	140	121	94	37	


b



# at risk	0	2	4	6	8	10
Lum A 247	236	211	181	148	70	
Lum B 125	118	102	86	62	21	


DDFS by St Gallen subtype and histological grade

a




# at risk	0	2	4	6	8	10
Lum B G1 23	23	23	21	19	7	
Lum A G1-2 350	338	308	277	232	120	
Lum B G2-3 148	139	117	100	75	30	
Lum A G3 40	35	30	27	22	17	

b




# at risk	0	2	4	6	8	10
Lum B G1 9	9	9	9	9	8	3
Lum A G1-2 218	211	191	164	134	61	
Lum B G2-3 116	109	93	77	54	18	
Lum A G3 29	25	20	17	14	9	

DDFS in ER+/HER2-normal/G2



# at risk	0	2	4	6	8	10
PgR+ 346	332	296	262	222	139	
PgR- 67	65	54	45	30	8	



# at risk	0	2	4	6	8	10
Ki67 low 357	343	306	266	220	134	
Ki-67 high 56	54	44	41	32	13	

Table 1. Patient and tumor characteristics

Factor	Patient material I SB22-pre N (%)	Patient material II SB22-post N (%)	Patient material III BMM N (%)	Total I+II+III N (%)
Number of patients	185	103	273	561
Age				
Median, years	46	65	58	54
Range, years	36–56	43–81	37–88	36–88
Menopausal status				
Premenopausal	185 (100)	0	47 (17)	232 (41)
Postmenopausal	0	103 (100)	225 (83)	328 (59)
Unknown	0	0	1	1
Tumor size				
T1	79 (43)	37 (36)	206 (75)	322 (57)
T2	106 (57)	66 (64)	67 (25)	239 (43)
Median, mm	22	22	15	20
Range, mm	2–50	2–50	1–45	1–50
‘Lum A-like’	151 (82)	65 (63)	174 (64)	390 (70)
‘Lum B-like (HER2-neg)’	34 (18)	38 (37)	99 (36)	171 (30)
Lymph nodes				
Negative	63 (34)	36 (35)	193 (71)	292 (52)
1 Positive	56 (30)	36 (35)	50 (18)	142 (25)
2 Positive	40 (22)	19 (18)	21 (8)	80 (14)
3 Positive	26 (14)	12 (12)	9 (3)	47 (8)
ER status				
Positive	185 (100)	103 (100)	273 (100)	561 (100)
PgR status				
Negative	10 (5)	30 (29)	58 (21)	98 (17)
Positive	175 (95)	73 (71)	215 (79)	463 (83)
Histological grade				
G1	35 (19)	6 (6)	84 (31)	125 (22)
G2	104 (56)	85 (83)	156 (57)	345 (62)
G3	46 (25)	12 (12)	33 (12)	91 (16)
Ki-67				
Low	160 (86)	88 (85)	217 (79)	465 (83)
High	25 (14)	15 (15)	56 (21)	96 (17)
HER-2 status				
Negative	185 (100)	103 (100)	273 (100)	561 (100)

Adjuvant treatment				
Endocrine therapy	88 (48)	103 (100)	181 ^a (66)	372 ^a (66)
Chemotherapy	0	0	9 ^a (3)	9 ^a (2)
None	97 (52)	0 (0)	89 (33)	186 (33)
DDFS 10 years				
Number of patients ^b	125 (68)	76 (74)	236 (86)	437 (78)
Median, years	10	5.7	8.9	9.3
Range, years	10–10	2.5–10	6.2–10	2.5–10

^a Six patients received endo-chemotherapy

^b Number of patients alive without metastasis at last follow-up (truncated at 10 years).

Table 2. Patient and tumor characteristics of ‘Luminal A-like’ vs. ‘Luminal B-like (HER2-negative)’

Factor	‘Luminal A-like’ N (%)	‘Luminal B-like (HER2-neg)’ N (%)
Number of patients	390	171
Material I SB22-pre	151 (38)	34 (20)
Material II SB22-post	65 (17)	38 (22)
Material III BMM	174 (45)	99 (58)
Age		
Median, years	53	58
Range, years	36–88	37–86
Menopausal status		
Premenopausal	182 (47)	50 (29)
Postmenopausal	208 (53)	120 (71)
Unknown	0	1
Tumor size		
Median, mm	19	20
Range, mm	1–50	2–45
Lymph nodes		
Negative	189 (48)	103 (60)
1 Positive	103 (26)	39 (23)
2 Positive	65 (17)	15 (9)
3 Positive	33 (8)	14 (8)
PgR status		
Negative	0 (0)	98 (57)
Positive	390 (100)	73 (43)
Histological grade		
G1	102 (26)	23 (13)
G2	248 (64)	97 (57)
G3	40 (10)	51 (30)
Ki-67		
Low	390 (100)	75 (44)
High	0 (0)	96 (56)
Adjuvant endocrine therapy		
Yes	247 (63)	125 (73)
No	143 (37)	46 (27)
Adjuvant chemotherapy		
Yes	4 (1)	5 (3)
No	386 (99)	166 (97)

Adjuvant chemo and/or endocrine therapy

Yes	248 (64)	127 (74)
No	142 (36)	44 (26)

Events, <10 years follow-up

Alive, no metastasis	307	130
Distant metastasis	69	34

Table 3a. Multivariable analysis of all patients (N = 561; stratified for patient material)

Factor	Hazard ratio	95% Confidence interval	<i>P</i> -value
Grade 2 vs. 1	2.8	1.3 – 6.0	0.006
Grade 3 vs. 1	4.4	2.0 – 11	<0.001
‘Luminal A-like’ vs.			
‘Luminal B-like’	1.2	0.77 – 1.9	0.40
T2 vs. T1	1.3	0.85 – 2.0	0.22
N1 vs. N0	1.6	1.03 – 2.5	0.036
Age (cont.)	1.0	0.99 – 1.05	0.23

Table 3b. Multivariable analysis of patients treated with endocrine therapy (N=372; stratified for patient material)

Factor	Hazard ratio	95% Confidence interval	<i>P</i> -value
Grade 2 vs. 1	5.3	1.3 – 22	0.023
Grade 3 vs. 1	9.6	2.2 – 42	0.003
‘Luminal A-like’ vs.			
‘Luminal B-like’	1.2	0.72 – 2.1	0.45
T2 vs. T1	1.7	0.97 – 2.8	0.066
N1 vs. N0	2.0	1.2 – 3.5	0.009
Age (cont.)	1.0	0.99 – 1.06	0.10
